Skip to content

Enfortumab vedotin and MMAE concentration-input reference

Fixed effective ADC decay coupled to MMAE formation and loss under externally specified concentration inputs.

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin ↗

Journal of Pharmacokinetics and Pharmacodynamics

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does the DDI preset change ADC and payload exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Single 24.9 µg/mL ADC input

Authored exploratory concentration-input condition with fixed effective coefficients. Inputs are externally prescribed ADC concentration increments; no dose-to-concentration conversion or clinical prediction is specified.

0–7 day

Scenario details

Single 24.9 µg/mL ADC input

Authored exploratory concentration-input condition with fixed effective coefficients. Inputs are externally prescribed ADC concentration increments; no dose-to-concentration conversion or clinical prediction is specified.

Readouts

ADC concentration · ug/mL
Model-derived concentration-domain quantity in the stated physical unit.
MMAE concentration · ng/mL
Model-derived concentration-domain quantity in the stated physical unit.
Cumulative ADC exposure · ug*day/mL
Model-derived concentration-domain quantity in the stated physical unit.
Cumulative MMAE exposure · ng*day/mL
Model-derived concentration-domain quantity in the stated physical unit.
ADC accounted · ug/mL
ADC concentration plus accumulated ADC concentration loss; compare with externally delivered concentration increments.

Study purpose

  • How do the model's key biological readouts change under single 24.9 µg/ml adc input?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
7 → 168

Time between reported samples.

day
0.05 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Fixed effective ADC decay coupled to MMAE formation and loss under externally specified concentration inputs.

Fixed effective ADC decay coupled to MMAE formation and loss under externally specified concentration inputs.

Model details

4 parameters · 5 states · 5 equations · 13 derived outputs

Classification & API access
Therapeutic
Enfortumab vedotin and MMAE
Modality
Antibody–drug conjugate (ADC)
Target
PVRL4, Nectin-4
Disease / scope
Fixed ADC and payload exposure research conditions
ParameterDefaultUnitDescription
Effective ADC decay coefficientadc_decay_day0.77329192546583841/dayFixed effective coefficient for loss of ADC concentration.
Effective MMAE loss coefficientmmae_elimination_day0.22725644141/dayFixed first-order coefficient for loss of MMAE concentration.
Effective MMAE formation coefficientmmae_formation_ng_ml_day_per_ug_ml0.1186(ng/mL/day)/(µg/mL)Fixed coupling coefficient from ADC concentration to MMAE formation rate.
Fixed clock coefficientvalidation_run_nonce0—Zero-effect constant in the elapsed-time observer; no kinetic or biological role.

Related models

SKB264 tumor-growth inhibitionInotuzumab ozogamicin conditional pharmacokineticsT-DM1 and T-DXd conditional intact-ADC pharmacokineticsCharged trastuzumab ADC plasma disposition

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics